HC Wainwright Forecasts Surrozen FY2030 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Analysts at HC Wainwright issued their FY2030 earnings estimates for Surrozen in a research report issued on Tuesday, March 24th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($3.54) for the year. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share.

Several other research firms have also recently commented on SRZN. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 target price on shares of Surrozen in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.00.

Surrozen Price Performance

Shares of Surrozen stock opened at $26.14 on Wednesday. The stock’s 50 day simple moving average is $24.34 and its 200-day simple moving average is $18.81. The stock has a market cap of $224.02 million, a P/E ratio of -0.78 and a beta of 0.53. Surrozen has a 1-year low of $5.90 and a 1-year high of $29.59.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($6.30). Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%. The business had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million.

Insider Buying and Selling

In other Surrozen news, major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the stock in a transaction that occurred on Tuesday, March 24th. The stock was bought at an average cost of $24.69 per share, for a total transaction of $2,633,386.02. Following the completion of the transaction, the insider owned 736,554 shares of the company’s stock, valued at approximately $18,185,518.26. The trade was a 16.93% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Group Gp Lp Column III bought 18,052 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the purchase, the insider owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. The trade was a 1.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 330,291 shares of company stock valued at $7,478,785 in the last 90 days. Insiders own 45.18% of the company’s stock.

Hedge Funds Weigh In On Surrozen

Large investors have recently modified their holdings of the business. Braidwell LP acquired a new stake in shares of Surrozen during the 2nd quarter worth about $1,252,000. Stempoint Capital LP raised its holdings in Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the period. Armistice Capital LLC acquired a new position in Surrozen in the second quarter valued at about $536,000. Geode Capital Management LLC lifted its position in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in Surrozen during the fourth quarter worth about $928,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Key Stories Impacting Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Major shareholder TCG Crossover GP II purchased 106,658 shares on March 24 at an average $24.69, increasing its stake ~16.9% to 736,554 shares — a strong insider-buy signal that can support the stock. SEC Filing
• Positive Sentiment: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90, a smaller follow-on purchase that further signals insider confidence. SEC Filing
• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating with a $40 price target — a materially higher valuation that may attract buyers. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and raised its target to $36. Its analyst also issued a FY2030 EPS forecast (-$3.54), notably less negative than the broader consensus, signaling a more optimistic long-term view. TickerReport
• Neutral Sentiment: Short-interest reports for March show zero shorted shares and a 0.0 days-to-cover metric, but the entries include NaN and look inconsistent — treat this as unreliable data rather than a clear market signal.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.